Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.71 |
| ▸ | PPARG | P37231 | 3/20 | 0.71 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.71 |
| ▸ | RXRA | P19793 | 2/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.71 |
| ▸ | CNR1 | P21554 | 4/20 | 0.64 |
| ▸ | CNR2 | P34972 | 4/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.57 |
| ▸ | F7 | P08709 | 3/20 | 0.57 |
| ▸ | F3 | P13726 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22451075 | 1.00 | ALDH1A1 (0.71) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL3408523 | 1.00 | ALDH1A1 (0.71) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL3407181 | 1.00 | ALDH1A1 (0.71) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL15335275 | 1.00 | ALDH1A1 (0.71) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL16450794 | 0.94 | MAPT (0.67) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL3411078 | 0.94 | MAPT (0.67) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL652501 | 0.91 | MAPT (0.81) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL652290 | 0.91 | MAPT (0.81) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL12961411 | 0.91 | MAPT (0.81) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL654221 | 0.91 | MAPT (0.81) | ALDH1A1MAPTCYP19A1PPARGOXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250216407-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. | 2025-07-03 | — | — | US | claimed |
| WO-2023192314-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-12 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250216407-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2024229108-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2023192314-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008070129-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008057283-A2 | USE OF RESOLVINS FOR INHIBITION OF BONE LOSS | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008011085-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007127377-A2 | COMBINATIONS COMPRISING OMEGA-3 FATTY ACID COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | ALOX15B, ALOX5, ALOX15 | ALDH1A1 1517/4885MAPT 4520/4885CYP19A1 693/4885 |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | ALDH1A1 266/4885MAPT 2470/4885CYP19A1 763/4885 |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | ALOX15B, ALOX12, ALOX15 | ALDH1A1 1031/4885MAPT 3903/4885CYP19A1 226/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | ALDH1A1 182/4885MAPT 4272/4885CYP19A1 1234/4885 |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | ALOX15B, ALOX5, ALOX12 | ALDH1A1 3157/4885MAPT 4741/4885CYP19A1 196/4885 |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | ALDH1A1 266/4885MAPT 2470/4885CYP19A1 763/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | ALDH1A1 756/4885MAPT 2450/4885CYP19A1 21/4885 |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | SNCA, PARK7, PYGB | ALDH1A1 3248/4885MAPT 12/4885CYP19A1 4850/4885 |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | ALOX5, ALOX15, ALOX15B | ALDH1A1 2772/4885MAPT 2662/4885CYP19A1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.